1 of 60

Sarcoidosis

M. Dankyau

June 2023

2 of 60

Outline

Case studies

Introduction

Pathophysiology

Clinical features

Investigations

Treatment and Prognosis

Summary/Review questions

Conclusion

3 of 60

Case studies

4 of 60

Case 1 – Slide 1

  • A 34-year-old woman comes to the clinic because of a 3-day history of right-sided facial droop. ROS reveals headache, blurry vision, cough, and dyspnoea. Temperature is 37.1°C, pulse 80/min, RR 16/min, and BP 136/72mmHg. Examination shows a rash on both legs (tender erythematous nodules) and plaques at the base of her neck. Right-side facial weaknesses is confirmed but no other neurological anomalies. Her eyes appear red and watery.

  • System(s) responsible
    • A. CNS
    • B. CVS
    • C. Musculoskeletal
    • D. Respiratory

5 of 60

Case 1 – Slide 2

  • A 34-year-old woman comes to the clinic because of a 3-day history of right-sided facial droop. ROS reveals headache, blurry vision, cough, and dyspnoea. Temperature is 37.1°C, pulse 80/min, RR 16/min, and BP 136/72mmHg. Examination shows a rash on both legs (tender erythematous nodules) and plaques at the base of her neck. Right-side facial weaknesses is confirmed but no other neurological anomalies. Her eyes appear red and watery.

  • Differential diagnoses 
    • A. Bell’s palsy
    • B. Dermatomyositis
    • C. Sarcoidosis
    • D. Stroke
    • E. Systemic Lupus erythematosus

6 of 60

Introduction

7 of 60

Sarcoidosis

  • sarcoid refers to the flesh
  • and osis means disorder
  • sarcoidosis is an immunologic disorder that results in lots of small nodules forming throughout the body.

8 of 60

Introduction 1

  • Sarcoidosis is a systemic, multi-organ, granulomatous disease of unknown aetiology, characterized by the presence of granuloma in various organs
  • It can affect almost any organ in the body, but the most affected are the lungs

9 of 60

Introduction 2

  • Usually associated with chest symptoms but also multiple extra-pulmonary manifestations e.g. erythema nodosum and lymphadenopathy.
  • Symptoms can vary from asymptomatic (in up to 50%) to severe and life-threatening.
  • Two spikes in incidence: in young adulthood and again around age 60.
  • Women are affected more often, and occurs more frequently in black people compared with other ethnic groups.

10 of 60

Pathophysiology

11 of 60

Pathophysiology 1

  • Normally, cells of the immune system are ready to spot and destroy any foreign pathogens that could cause the body harm.
  • In sarcoidosis, this process occurs over and over throughout the body without the presence of a specific pathogen that the body is trying to destroy.
  • Immune system seems to be going haywire in the absence of a pathogen.

12 of 60

Pathophysiology 2

Precise trigger is unknown, but there are some known risk factors

Genetic risk factors

    • Class I and II human leukocyte antigen (HLA) molecules
    • Being African
    • Having a family member with sarcoidosis.

Environmental risk factors

    • Prior infection with Mycobacterium tuberculosis and Borrelia burgdorferi
    • Note that these pathogens are long gone when the autoimmune problem sets in.

13 of 60

Spirochetes & Mycobacteria

14 of 60

Pathophysiology 3

Some drugs and exposures also associated with development of sarcoidosis and sarcoid-like granulomatosis.

Patients undergoing antiviral therapy for chronic hepatitis C

*monotherapy with IFN-alpha

*combination therapy with IFN-alpha and ribavirin

    • .

15 of 60

Pathological changes

Granulomas in sarcoidosis are noncaseating - there is no tissue necrosis at the centre of the granuloma, unlike other granulomatous diseases like tuberculosis.

Macrophages fuse together to form a single large multinucleated cell called a Langhans giant cell.

16 of 60

17 of 60

Pathological changes 2

  • Increased blood calcium level caused by excess Vitamin D produced by macrophages.
  • Increased level of angiotensin converting enzyme (ACE), which is produced by T cells.
  • Elevated levels of T cells in the lungs on bronchoalveolar lavage.

18 of 60

Clinical features

19 of 60

Systemic Symptoms

Fever

Fatigue

Weight loss

20 of 60

Lungs (affecting over 90%)

  • Mediastinal lymphadenopathy
  • Pulmonary fibrosis
  • Pulmonary nodules

21 of 60

Liver (affecting 20%)

  • Liver nodules
  • Cirrhosis
  • Cholestasis

22 of 60

Eyes (affecting 20%)

  • Conjunctivitis
  • Uveitis
  • Optic neuritis

23 of 60

Skin (affecting 15%)

  • Erythema nodosum (tender, red nodules on the shins caused by inflammation of the subcutaneous fat)
  • Lupus pernio (raised, purple skin lesions commonly on cheeks and nose)
  • Granulomas in scar tissue

24 of 60

Lupus pernio

25 of 60

Heart (affecting 5%)

  • Bundle branch block
  • Heart block
  • Myocardial muscle involvement

26 of 60

Kidneys (affecting 5%)

  • Kidney stones (due to hypercalcaemia)
  • Nephrocalcinosis
  • Interstitial nephritis

27 of 60

Central nervous system (5%)

  • Nodules
  • Pituitary involvement (diabetes insipidus)
  • Encephalopathy
  • Facial nerve palsy

28 of 60

Peripheral Nervous System (5%)

  • Mononeuritis multiplex
  • (painful, asymmetrical, asynchronous sensory and motor peripheral neuropathy involving isolated damage to at least 2 separate nerve areas)

29 of 60

Musculoskeletal system(2%)

  • Arthralgia
  • Arthritis
  • Myopathy

30 of 60

Lofgren’s Syndrome

  • Characterised by a triad of:
    • Erythema nodosum
    • Bilateral hilar lymphadenopathy
    • Polyarthralgia (joint pain in multiple joints)

31 of 60

Heerfordt-Waldenström syndrome

  • A rare subacute variant of sarcoidosis characterized by:
    • enlargement of the parotid or salivary glands
    • facial nerve paralysis
    • anterior uveitis.
  • Granulomas with a peripheral lymphocyte deficit are found in the affected organs.

32 of 60

Staging based on Chest radiograph

  • 0: No lung involvement�I: Bilateral lymphadenopathy (LAD)�II: LAD + infiltrates�III: Parenchymal disease but no LAD�IV: Pulmonary fibrosis

33 of 60

Differential diagnosis: Granulomatous lung disease

  • Infectious conditions
    • Tuberculosis
    • Atypical mycobacterial infections
    • Invasive fungal infections - histoplasmosisaspergillosisblastomycosis, or Pneumocustis Jirovecii

34 of 60

Differential diagnosis: Granulomatous lung disease

  • Hypersensitivity pneumonitis
    • Pneumoconiosis
    • Drug-induced hypersensitivity pneumonitis

35 of 60

Differential diagnosis: Granulomatous lung disease

  • Foreign body granulomatosis

36 of 60

Differential diagnosis: Granulomatous lung disease

  • Vasculitides
    • Granulomatosis with polyangiitis
    • Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
    • Pulmonary lymphomatoid granulomatosis

37 of 60

38 of 60

Investigations

39 of 60

Histology

Gold standard for confirming the diagnosis of sarcoidosis is by histology from a biopsy.

Usually by doing bronchoscopy with ultrasound guided biopsy of mediastinal lymph nodes.

Histology shows characteristic non-caseating granulomas with epithelioid cells.

40 of 60

Caseating vs Noncaseating granuloma

41 of 60

Langhans giant cell

42 of 60

Blood Tests

  • Raised serum ACE.
    • Often used as a screening test.
  • Hypercalcaemia is a key finding.
  • Raised serum soluble interleukin-2 receptor
  • Raised C-Reactive Protein
  • Raised immunoglobulins

43 of 60

Imaging

Chest xray shows hilar lymphadenopathy

High-resolution CT thorax shows hilar lymphadenopathy and pulmonary nodules

MRI scan show CNS involvement

PET scan can show active inflammation in affected areas

44 of 60

Chest radiograph in sarcoidosis

45 of 60

High Resolution CT - Hilar lymphadenopathy

46 of 60

Tests for other organ involvement

  • U&E for kidney involvement
  • Urine dipstick or urine albumin-creatinine ratio for proteinuria indicating nephritis
  • LFTs for liver involvement
  • ECG and echocardiogram for heart involvement
  • Ultrasound abdomen for liver and kidney involvement
  • Ophthalmology review for eye involvement

47 of 60

Treatment and prognosis

48 of 60

Treatment

  • No treatment is considered as first line in patients with no or mild symptoms as the condition often resolves spontaneously.
  • Oral steroids are usually first line where treatment is required and given for between 6 to 24 months.
    • Patients should be given bisphosphonates to protect against osteoporosis while on such long-term steroids.
  • Second line options are methotrexate or azathioprine
  • Lung transplant is rarely required in severe pulmonary disease

49 of 60

Prognosis

Spontaneously resolves within 6 months in around 60% of patients.

In a small number of patients, it progresses with pulmonary fibrosis and pulmonary hypertension, potentially requiring a lung transplant.

Death usually occurs when it affects the heart (causing arrhythmias) or the central nervous system.

50 of 60

Summary

51 of 60

Flash cards

52 of 60

Questions

53 of 60

Flashcard 1

  • What is the most common sign of sarcoidosis?
    • Lymphadenopathy

54 of 60

Flashcard 2

  • What is the characteristic pathologic feature of sarcoidosis?
  • Non-caseating granuloma

55 of 60

Flashcard 3

  •  List 5 organs most commonly affected by sarcoidosis.
    • Lymph node
    • Lungs
    • Liver
    • Skin
    • Eyes

56 of 60

Flashcard 4

  • Angiotensin converting enzyme levels (decrease/increase)            in sarcoidosis.

57 of 60

Summary

  •  Sarcoidosis is a systemic disease that can affect any organ, with the lungs and intrathoracic lymph nodes being the most frequently affected sites.
  • Diagnosis relies on the presence of noncaseating granuloma on histopathologic examination, compatible clinical presentation, and exclusion of other causes of granulomatous inflammation.
  • Treatment is reserved for patients with disabling symptoms or progressive organ damage/dysfunction because spontaneous remission is frequent.
  • Glucocorticoids are first-line therapy, whereas glucocorticoid-sparing agents and biologic agents are used in refractory/recurrent cases

58 of 60

59 of 60

Conclusion

60 of 60

Bibliography

  • Gupta R et al (2021). Sarcoidosis: An FP’s primer on an enigmatic disease
  • Kaloga M et al. (2015). Epidemiological, Clinical, and Paraclinic Aspect of Cutaneous Sarcoidosis in Black Africans
  • Osmosis.org. (2021). Sarcoidosis
  • Ungprasert P et al (2019). Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
  • Zerotofinals.com. (2019). Sarcoidosis